
Rapamycin
CAS No. 53123-88-9
Rapamycin( Sirolimus )
Catalog No. M14886 CAS No. 53123-88-9
A macrolide compound that has potent immunosuppressive and antiproliferative properties by inhibiting mTOR (IC50=0.1 nM).
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
25MG | 36 | In Stock |
![]() ![]() |
50MG | 43 | In Stock |
![]() ![]() |
100MG | 58 | In Stock |
![]() ![]() |
200MG | 99 | In Stock |
![]() ![]() |
500MG | 186 | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameRapamycin
-
NoteResearch use only, not for human use.
-
Brief DescriptionA macrolide compound that has potent immunosuppressive and antiproliferative properties by inhibiting mTOR (IC50=0.1 nM).
-
DescriptionA macrolide compound that has potent immunosuppressive and antiproliferative properties by inhibiting mTOR (IC50=0.1 nM).Other Indication Approved(In Vitro):Rapamycin (GMP) (1 nM; 2-3 weeks) induces in vitro differentiation of human embryonic stem cell (hESCs) into mineralized osteoblasts.Rapamycin (GMP) (1 nM; 2-3 weeks) enhances the osteoblastic differentiation of human embryoid bodies (hEBs).Rapamycin (GMP) (20 nM; 4 h) serum-dependently promotes vascular smooth muscle cells (VSMCs) differentiation.Rapamycin (GMP) induces osteoblastic differentiation in rat osteoblast-like osteosarcoma cells.
-
In VitroRapamycin (GMP) (1 nM; 2-3 weeks) induces in vitro differentiation of human embryonic stem cell (hESCs) into mineralized osteoblasts.Rapamycin (GMP) (1 nM; 2-3 weeks) enhances the osteoblastic differentiation of human embryoid bodies (hEBs).Rapamycin (GMP) (20 nM; 4 h) serum-dependently promotes vascular smooth muscle cells (VSMCs) differentiation.Rapamycin (GMP) induces osteoblastic differentiation in rat osteoblast-like osteosarcoma cells.
-
In Vivo——
-
SynonymsSirolimus
-
PathwayPI3K/Akt/mTOR signaling
-
TargetmTOR
-
RecptormTOR
-
Research AreaOther Indications
-
IndicationOther Disease
Chemical Information
-
CAS Number53123-88-9
-
Formula Weight914.1719
-
Molecular FormulaC51H79NO13
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 28 mg/mL
-
SMILESC[C@@H](C([C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(C[C@@H]([C@H](C)C[C@@H]1CC[C@@H](O)C(OC)C1)OC2=O)=O)=O)C[C@H](C)/C=C/C=C/C=C(C)/[C@@H](OC)C[C@H]3O[C@](C(C(N4[C@H]2CCCC4)=O)=O)(O)[C@H](C)CC3
-
Chemical NameRapamycin
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Morris RE, et al. Transplant Proc. 1991 Feb;23(1 Pt 1):521-4.
2. Dumont FJ, et al. J Immunol. 1990 Jan 1;144(1):251-8.
3. Dumont FJ, et al. J Immunol. 1990 Feb 15;144(4):1418-24.
4. Edwards SR, et al. J Biol Chem. 2007 May 4;282(18):13395-401.
molnova catalog



related products
-
SR9011
SR9011 is a REV-ERB agonist (IC50: 790 nM, REV-ERBα; IC50: 560 nM, REV-ERBβ).
-
mTOR inhibitor-1
C-4 is a potential ATP-competitive inhibitor of mTOR. C-4 could inhibit cell growth and proliferation.
-
PRT-060318
PRT-060318 (PRT318) is a novel selective inhibitor of the Syk tyrosine kinase, as an approach to HIT treatment.